The AI platform for
Investor Relations
Manage investor dialogue at scale — grounded in your data, controlled by your team.
They trust us
IR Impact
Before
2–3 weeks
With OpenIR
2–3 hours
Before
4–6 hours
With OpenIR
15 minutes
Before
Scattered, manual
With OpenIR
Instant, cited
Why OpenIR
Built for the rigour
investor relations demands
Generic AI tools hallucinate, lack compliance controls, and don't understand regulated financial communication. OpenIR is purpose-built for IR teams.
Auditable source attribution
Every answer comes with citations linked back to the original document — annual reports, regulatory filings, earnings transcripts. Full audit trail for compliance and investor scrutiny.
Regulatory alignment
Answers grounded exclusively in your approved documents. No hallucinated claims, no compliance risk. Aligned with AMF guidelines and European disclosure standards.
Guidance consistency
Maintain one source of truth across earnings prep, investor emails, and live dialogue. Detect contradictions before they reach the market.
Continuous learning
Your corrections train the AI. It learns your company's voice, your boundaries, and your narrative — getting sharper with every interaction.
EU-native infrastructure
All data processed and stored in European data centres. SOC 2 Type I certified, GDPR compliant. Your MNPI never leaves your secure environment.
Human-in-the-loop by design
Your IR team reviews and approves every response. The AI drafts, your team decides. No autonomous investor communication — ever.
Product
Reinvented infrastructure
for IR teams
Integrated AI solutions to transform IROs' work and put them at the centre of Investor Dialogue.
01 — Knowledge Library
Knowledge Library
Centralise every document into a single, AI-ready platform.
- Universal ingestion — PDFs, Word, Excel, web pages, financial models
- Fine-grained control — choose what's indexed and how it shapes your narrative
- Connected sources — sync Google Drive, SharePoint, and more
| Name | Folder | Type | Published |
|---|---|---|---|
| Q4 2025 Key Messages & Talking Points | Internal Guidance | Key Messages | Dec 01, 2025 |
| Sell-Side Consensus Summary — Nov 2025 | Analyst Coverage | Consensus | Nov 15, 2025 |
| Shareholder Base Analysis Q3 2025 | Analyst Coverage | Analysis | Oct 30, 2025 |
| Q3 2025 Earnings Transcript | Earnings Reports | Transcript | Oct 22, 2025 |
| Capital Markets Day 2025 | Investor Events | Presentation | Sep 15, 2025 |
| Investor FAQ — NEXAGEN Franchise | Internal Guidance | FAQ | Sep 01, 2025 |
| Q2 2025 Earnings Press Release | Earnings Reports | Press Release | Jul 23, 2025 |
| Strategic Partnership with CellForge | Press Releases | Press Release | Jun 10, 2025 |
02 — Q&A Copilot
Q&A Copilot
Import questions from any channel. Get AI-drafted answers grounded in your knowledge base.
- Automated processing — import from emails, DDQ, files, or manual input
- Multi-team workflow — automated routing, coordinated review, messaging consistency
- Continuously learning — your edits feed back into the AI for better future answers
- Proactive Q&A building — develop strategic Q&As to address questions before they arise
| Query | From | Status | Assignee | Priority |
|---|---|---|---|---|
| What is your guidance for FY2026 revenue? | Goldman Sachs | Answered | SR | ●●● |
| Timeline for NEXAGEN Phase III readout? | J.P. Morgan | Answered | SR | ●●● |
| Update on COGNIVEX regulatory filing? | Morgan Stanley | Draft | MK | ●●○ |
| Cash position and financing plans for 2026? | Barclays | Pending | — | ●●○ |
| R&D spend breakdown by therapeutic area? | Citi | Pending | — | ●○○ |
| IP portfolio and patent expiry schedule? | Jefferies | Draft | SR | ●○○ |
| Manufacturing capacity and CDMO strategy? | UBS | Pending | — | ●○○ |
| Competitive positioning vs. peer compounds? | Deutsche Bank | Answered | MK | ●●● |
03 — Live Dialogue
Live Dialogue
Deploy custom-fit AI-powered conversations with investors.
- Real-time AI — 24/7 sourced live responses, collects feedback and insight, no intermediaries
- Fully customisable — your branding, your domain, your narrative journey delivered to investors
- Thoroughly evaluated — agents tested in full transparency before production deployment
1. Revenue growth of 23% YoY driven by strong NEXAGEN uptake in the U.S. and EU markets, reaching $847M in quarterly revenue.1
2. Phase III data readout for COGNIVEX expected in Q1 2026, with the company reporting positive interim results from the pivotal trial.2
3. Updated FY2025 guidance raised to $3.2–3.4B, reflecting strong commercial momentum and pipeline progress.1
4. Strategic partnership with CellForge Therapeutics to co-develop next-gen delivery platforms, with $120M upfront payment.3
04 — Draft Assistant
Draft Assistant
AI-assisted document drafting with inline editing — earnings scripts, press releases, investor comms.
- Inline editing — review and refine AI-generated content directly in the document
- Context-aware — attach financials, prior scripts, and guidelines
- Tone of voice — trained on your company's communication style
Opening Remarks
Thank you, operator, and good morning everyone. Welcome to Lumina Biosciences' third quarter 2025 earnings call. I'm Sarah Reeves, Head of Investor Relations.
Joining me today are Dr. James Chen, our Chief Executive Officer, and Maria Kowalski, our Chief Financial Officer.
Financial Highlights
Third quarter revenue reached $847 million, representing 23% growth year-over-year. This was driven primarily by continued strong uptake of NEXAGEN across U.S. and European markets.
Operating income was $192 million, with an operating margin of 22.7%, an improvement of 340 basis points compared to the prior year period.
Pipeline Update
We are pleased to report positive interim data from our pivotal Phase III trial for COGNIVEX. The Data Safety Monitoring Board has recommended continuation of the trial...
05 — Investor Targeting
Investor Targeting
Decode investor behaviour to identify the perspectives that fit your strategy.
- Multi-channel data — aggregate email, meetings, CRM, and dialogue signals
- Cross-source insights — map investors' strategic potential from every touchpoint
- Active engagement — connect with the right investors at the right moment
| Investor | Type | AUM | Fit Score | Status | Last Contact |
|---|---|---|---|---|---|
BM BlackRock Life Sciences |
Long Only | $42B | 92 |
Engaged | 2d ago |
FD Fidelity Healthcare |
Long Only | $38B | 88 |
Meeting Set | 1w ago |
WG Wellington Mgmt |
Long Only | $28B | 76 |
Prospecting | 2w ago |
OR OrbiMed Advisors |
Hedge Fund | $18B | 85 |
Engaged | 3d ago |
RA RA Capital Mgmt |
Crossover | $12B | 71 |
Cold | 1m ago |
PV Perceptive Advisors |
Hedge Fund | $9B | 82 |
Prospecting | 5d ago |
VS Vanguard Health |
Index | $65B | 54 |
Passive | — |
06 — Monitor & Research
Monitor & Research
Track peers, market moves, and investor sentiment in real time.
- Breaking news alerts — peer announcements, regulatory filings, analyst coverage
- Competitive intelligence — monitor earnings, guidance changes, and strategic moves
- Custom watchlists — configure sources and topics that matter to your company
Today's Alerts
NovaTech Pharma reported positive topline data from their NOVA-301 trial in Alzheimer's, potentially competing with COGNIVEX in the same patient population.
Reuters · 35 min ago
BioVance reported Q3 revenue of $1.2B (+18% YoY), beating consensus by 4%. Management raised FY guidance.
SEC Filing · 2h ago
GS initiated coverage on Lumina Biosciences with a Buy rating and $78 price target, citing strong pipeline optionality.
Analyst Note · 4h ago
The FDA has scheduled an advisory committee meeting for Jan 15, 2026 to review the NEXAGEN supplemental application.
FDA.gov · 6h ago
Platform
Purpose-built for Investor Relations.
Generic AI hallucinates. It lacks compliance controls. It doesn't understand investor relations. OPENIR is different.
Model agnostic
No vendor lock-in. We select the best model for each task and upgrade as new models release. Your AI stays cutting-edge without migration headaches.
Hallucination control
Source-quoted retrieval only. Multi-layer review systems with built-in IR compliance guardrails. Financial and company-specific rules enforced. Rigorous testing with transparent accuracy scoring.
Human-in-the-loop
Your IR team retains full control. Review, edit, and intervene when necessary. Corrections feed back into the system. The AI learns your voice over time.
IR-specific workflows
Purpose-built for every single task IR is responsible for, not a generic wrapper on ChatGPT. Native integrations with the sources that matter: AMF filings, earnings transcripts, and more.
Data governance & audit trail
Full data isolation per organisation. MNPI firewalled from public disclosure. Complete history of every interaction: who said what, when, and based on which sources.
Enterprise security
EU-hosted infrastructure. SOC 2 Type I certified. GDPR compliant. Multi-tenant architecture with dedicated or on-premise options. Access controls built for IR requirements.
Team
Built by industry experts
Deep expertise across leading financial institutions and technology companies.
Alexandre Bouvier
Co-founder & CEO
Boussard & Gavaudan, Goldman Sachs
Mathieu Ripert
Co-founder & CTO
Instacart, Columbia University
Investors & Advisors
Backed by the industry
High-profile investment professionals.
Emmanuel Gavaudan
Boussard & Gavaudan
Jean-Robin Peters
BAML, AllianceBernstein
Louis Agon
Business Angel, Valtech
Charles-Edouard Joseph
Boussard & Gavaudan
Mathias Cornu
Igea, Exane
Security
We take security seriously
Built for regulated industries. Your data is isolated, encrypted, and hosted in Europe.
EU-hosted infrastructure
All data processed and stored in European data centres. No data leaves the EU.
Data isolation
Multi-tenant architecture with strict per-organisation data separation. Dedicated infra available.
Encryption
AES-256 at rest, TLS 1.3 in transit. End-to-end encryption for sensitive documents.
Compliance
SOC 2 Type I certified. GDPR compliant. Full audit trail for every interaction.
FAQ
What you need to know
about OpenIR
Built for European IR teams managing regulated communications across earnings seasons, investor roadshows, and continuous disclosure.
How does OpenIR ensure answers are accurate and sourced?
Every AI-generated answer includes citations linked to the original document — your URD, annual report, earnings transcript, or press release. Nothing is fabricated. Your team can verify every claim before it reaches an investor.
Can I control which documents the AI uses?
Yes. You choose what goes into the knowledge base and how it shapes responses. You can restrict answers to approved documents only, exclude draft materials, and set document-level permissions per team member.
How does it handle sensitive MNPI?
All data is processed in EU-hosted infrastructure with strict per-organisation isolation. Material non-public information never leaves your environment. Access controls ensure only authorised team members can view sensitive content.
Does it work with European regulatory filings?
Absolutely. OpenIR supports Universal Registration Documents (URDs), AMF filings, annual and half-year reports, earnings transcripts, investor presentations, and all standard European disclosure formats.
How does the AI learn our company's tone of voice?
Every time your team edits an AI-drafted response, those corrections feed back into the system. Over time, OpenIR learns your preferred phrasing, disclosure boundaries, and messaging style — producing drafts that sound like your IR team wrote them.
Can multiple team members review and approve responses?
Yes. OpenIR is built for team workflows — assign queries, review AI drafts, leave comments, and track who approved what. The full audit trail shows every human intervention.
Bring your latest annual report
and investor FAQ. We'll show you.
See OpenIR answer your real questions — in your voice, with your sources, in under an hour.
Book a demo